



Figure S1: Effect of amyirin on HIV-1 expression. Amyirin did not significantly ($p < 0.05$) induce HIV-1 expression in the latently infected monocytic cell line.


Figure S2: Effect of HHODC on HIV-1 PR ($n = 4$). The compound, fluorogenic substrate and HIV-1 PR were incubated at 37°C for 1 h. HHODC demonstrated inhibition of $< 50\%$ ($100 \mu\text{g}/\text{mL}$). AP=Acetyl pepstatin a known protease inhibitor was used as control.

Figure S3: Effects of HHODC on HDAC and PKC activities. (a) HDAC activity in HeLa cell lysate was measured by incubating substrate and samples in a reaction volume $100 \mu\text{L}$. Marginal HDAC inhibition was observed with 8 and $12.5 \mu\text{g}/\text{mL}$ of HHODC, while higher HHODC concentrations increased enzyme activity. (b) An insignificant ($p > 0.05$) 20% activation was observed at $8 \mu\text{g}/\text{mL}$ and 9% at $6 \mu\text{g}/\text{mL}$ compared to 80.7% for prostratin, the positive control.


Figure S4: Effect of HHODC on the viability of PBMCs. The concentration tested for endogenous cytokine production, $6.3 \mu\text{g}/\text{mL}$, was not toxic in PBMCs as illustrated. Auranofin was used as a positive control for toxicity. Percent cell viability in the presence of HHODC was 100%.







(a)



(b)

